Changchun High-tech (00066 1)
Changchun High-tech (00066 1) Technology Industry (Group) Co., Ltd. takes biopharmaceuticals, production and sales of Chinese patent medicines and real estate development as leading industries, supplemented by infrastructure construction and property management in development zones. The company's main products include polyethylene glycol recombinant human growth hormone injection, recombinant human growth hormone, recombinant human follicle stimulating hormone for injection, freeze-dried live attenuated varicella vaccine, rabies vaccine for human use, Xueshuanxinmaining tablets and Yin Hua Biyanling tablets.
Tongce Medical Treatment (600763)
The main business of Tongce Medical (600763) Co., Ltd. is medical services. The company's main products are medical services. The company is the vice chairman of Zhejiang Health Industry Federation, and won the top 50 most competitive listed companies in China Pharmaceutical (600056). For five years in a row, he was selected as one of the most potential listed companies in Forbes China 100, and was selected as one of the listed companies in Zhonglian 100 for many times. August 20 18 was included in the MSCI China a-share onshore index. 20 19 China capital annual meeting value list of listed companies 18, won the "Gold Quality-Most Growing Enterprise Award" of listed companies in shanghai securities news on 20 19, and was selected as one of the top 200 small and medium-sized listed companies in Asia on 20 19. 20 19 and 2020, BMC won the "China Excellent Management Company" jointly selected by Deloitte and Harvard Business Review for two consecutive years. In 2020, he was selected as one of the top 500 private enterprises of Hurun China and won the [Jin Zhihui Prize] in the financial sector. ...
Dean Diagnostics (300244)
Dean Diagnostics (300244) Technology Group Co., Ltd. is mainly engaged in medical diagnosis services and sales of in vitro diagnosis products. The company's main products and services are diagnostic services, diagnostic products, cold chain logistics, physical examination and financial leasing. In the field of cancer, the company continued to deepen the discipline construction and marketing power construction, and won the second place at the CSCO annual meeting in September. We have obtained three Class III registration certificates, 1 Class II registration certificate and 27 Class I products. At present, 1 three types of diagnostic products have entered the registration process.
Guangshengtang (300436)
Fujian Guangshengtang (300436) Pharmaceutical Co., Ltd. is mainly engaged in research and development, production and sales of nucleoside anti-hepatitis B virus drugs; The company's main products are anti-HBV drugs, liver protection drugs, digestive system drugs, respiratory system drugs, cardiovascular drugs and medical inspection services; At present, the company is a pharmaceutical company specializing in the field of liver health in China, and it is the only pharmaceutical company in China that has four first-choice drugs against hepatitis B virus: adefovir dipivoxil, lamivudine, entecavir and tenofovir.
Livzon (0005 13)
Livzon Pharmaceutical Group Co., Ltd. focuses on the research and development, production and sales of pharmaceutical products. Its main products include preparation products, raw materials, intermediates, diagnostic reagents and equipment. The main products are Yilian (iprazole enteric-coated tablets and iprazole sodium for injection), Livzon Dele (bismuth potassium citrate) series products, Yi Bei (leuprorelin acetate microspheres for injection), Lishenbao (urinary follicle-stimulating hormone for injection) and Le Baode (levofloxacin). Raw materials and intermediates, such as mevastatin, acarbose, colistin sulfate, phenylalanine and ceftriaxone sodium; Diagnostic reagent products such as AIDS virus antibody diagnostic reagent, mycoplasma pneumoniae antibody diagnostic reagent, treponema pallidum antibody diagnostic reagent.
Fosun Pharma (600 196)
Shanghai Fosun Pharma (600 196) (Group) Co., Ltd. is mainly engaged in pharmacy, medical devices, medical diagnosis and medical health services. The main products are core products in the fields of cardiovascular disease treatment, central nervous system disease treatment, blood system disease treatment, metabolic and digestive system disease treatment, anti-infection disease treatment, anti-tumor treatment, raw materials and intermediates. According to the 20 18 list of the top 100 enterprises in China pharmaceutical industry published by People's Republic of China (PRC), China Pharmaceutical Industry Information Center of the Ministry of Industry and Information Technology, the Group ranked seventh; According to IQVIA's statistics, the sales revenue of hospital prescription drugs produced by the group in 20 19 was ranked 10 in the whole country. As one of the largest manufacturers of antimalarial drugs in the world, the group has become a drug procurement center for global funds, UNICEF, WHO and African countries. ...
Mennuohua (603538)
Ningbo Meinuohua (603538) Pharmaceutical Co., Ltd. is mainly engaged in the research, development, production and sales of characteristic bulk drugs (including intermediates) and finished drugs. The main categories include cardiovascular drugs and gastrointestinal drugs. The main products of the company are valsartan, losartan, perindopril, rosuvastatin, atorvastatin, clopidogrel and esomeprazole, ticlopidine, duloxetine and mirtazapine. The company's important API production bases are all national high-tech enterprises, which have established strict quality management system and EHS management system, and passed GMP certification in European Union, China, Japanese and other regulatory markets. The company is one of the top 100 pharmaceutical internationalization enterprises in China, a high-quality supplier and partner in the international market (the top 60). Its core products cover cardiovascular, central nervous system, gastrointestinal tract and other therapeutic fields, and it is one of the enterprises with the largest variety of raw materials with European characteristics exported by China.
Hanshang Group (600774)
Hanshang Group (600774) Co., Ltd. is mainly engaged in pharmaceutical business, medical equipment business, commercial operation business and exhibition operation business, and its business model is joint venture+lease+brand agency. The group company was ranked among the top 100 enterprises in provinces and cities, and won the title of "the most growing listed company in the new retail industry" in the word-of-mouth list of listed companies in China, achieving safety and accident-free in the third1year. After the purchase of major assets is completed, the company will further put the underlying assets of the high-quality pharmaceutical manufacturing sector on the basis of the original business of the commercial sector.
Saisheng Pharmacy (300485)
Beijing Saisheng Pharmaceutical (300485) Co., Ltd. is mainly engaged in the research and development, production and sales of injections, and its leading product is biochemical drugs, which involves cardiovascular and cerebrovascular diseases, immune diseases (anti-tumor) and nervous system diseases. The company is the original research and drafting unit of national drug standards for five varieties of fibrinolytic enzyme, fibrinolytic enzyme injection, fibrinolytic enzyme for injection, Zhi Bo glycopeptide injection and deoxynucleotide sodium injection; Fibrinolytic enzyme injection, Zhi Bo glycopeptide injection, sodium deoxynucleotide injection and 100mg thymosin for injection are the first drugs produced in China. Tetrahexose monosialoganglioside sodium injection (GM- 1) and Zhi Bo glycopeptide injection are national key new products; Fibrinolytic enzyme, fibrinolytic enzyme injection, fibrinolytic enzyme for injection and thymosin for large-scale injection were rated as independent innovative products in Beijing. Lysozyme was separated from pure chemical fiber by immunoaffinity chromatography, and its pharmaceutical properties and the development of pharmaceutical preparations were obtained by Beijing Science and Technology. ...
Huada Gene (300676)
The main business of Shenzhen Huada Gene (300676) Co., Ltd. is to provide research services and comprehensive solutions for precision medical testing for scientific research institutions, enterprises and institutions, medical institutions and social health institutions through many groups of big data technologies such as genetic testing, mass spectrometry testing and bioinformatics analysis. The company's main products include pregnancy nutrition testing, human amino acid testing, human vitamin testing and so on. The company won the most respected enterprise and value partner award in China in 20 19, Golden Bull Award, Investor Relations Management Award in 20 18, CSI Golden Bauhinia Award, Best IR Team Award, First A-share Technology Leading 50 Carnival, Best Investor Service Award and Global Corporate Social Responsibility and Health Promotion Award. ...